All three PNH agents have cleared NICE via the standard Technology Appraisal route. The access question is settled; dosing convenience now decides NHS share.
NHS England commissions PNH complement-inhibitor therapy through 15 Highly Specialised Services (HSS)-designated centres, concentrated at Leeds, King's, Oxford, Addenbrooke's, and Glasgow, for an estimated 600 diagnosed UK patients. Ravulizumab (Ultomiris) holds the NHS anchor position, having cleared NICE as a standard Technology Appraisal (TA698, published 19 May 2021) on the strength of its q8w dosing versus eculizumab's q2w regimen. Despite PNH's ultra-rare prevalence, ravulizumab did not use NICE's Highly Specialised Technology (HST) pathway. It met the standard TA cost-effectiveness bar at its negotiated NHS price, the same route the rest of the class has since followed.
Iptacopan (Fabhalta) has since cleared its own standard Technology Appraisal as TA1000, NICE's 1,000th published appraisal, with a final positive recommendation now in place. The access uncertainty around its estimated £350,000 to £400,000 annual WAC has been resolved in the drug's favour, and NHS access no longer runs through Individual Funding Request. Crovalimab (Piasky) has also been recommended by NICE, for patients aged 12 and over weighing at least 40kg, on the strength of COMMODORE 2 data. Its subcutaneous self-injection every four weeks is now a live convenience argument in market, not a pending one.
Approved PNH agents — UK
| Drug (Brand / INN) | Mechanism | Company | UK Approval / NICE Status | Key Trial Result | NHS Commissioning |
|---|---|---|---|---|---|
| Ultomiris (ravulizumab) | Anti-C5 mAb IV q8w | AstraZeneca / Alexion | MHRA approved 2018; NICE TA698 recommended (standard Technology Appraisal, May 2021) | HERCULES: preferred over eculizumab on q8w vs q2w convenience | NHS England HSS commissioned; ~15 designated centres; ~600 UK patients on anti-C5 |
| Fabhalta (iptacopan) | Oral Factor B inhibitor | Novartis | MHRA approved 2024; NICE TA1000 recommended (NICE's 1,000th appraisal) | APPLY-PNH: 82% Hgb responder | NICE TA1000 recommended; est. £350,000–400,000/year WAC |
| Piasky (crovalimab) | Anti-C5 SC recycling mAb | Roche | MHRA approved 2024; NICE recommended (patients aged 12+, ≥40kg) | COMMODORE 1 & 2: non-inferior to eculizumab | NICE recommended; SC q4w self-injection is a live convenience argument in market |
Sources: MHRA drug approvals; NICE TA698 Ravulizumab for PNH (2021); NICE TA1000 Iptacopan for PNH; APPLY-PNH (Risitano et al., NEJM 2023); COMMODORE 1 & 2 trial data; NHS England Highly Specialised Services specification for PNH (2022).
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- NICE standard TA outcomes for all three agents (ravulizumab TA698, iptacopan TA1000, crovalimab's COMMODORE 2-based recommendation)
- why the HST pathway wasn't used despite PNH's ultra-rare status
- access implications now that all three are recommended
Delivers
- Centre-by-centre NHS HSS commissioning map (Leeds, King's, Oxford, Addenbrooke's, Glasgow)
- ravulizumab switch-programme mechanics
- consultant-level prescriber concentration
Delivers
- TA1000 iptacopan recommendation terms
- crovalimab's NICE recommendation for patients 12 and over weighing at least 40kg, based on COMMODORE 2
- comparative convenience positioning across IV q8w, oral, and SC q4w now that access is resolved for all three
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why NHS England commissions PNH therapy through 15 Highly Specialised Services centres for an estimated 600 diagnosed UK patients
- How patient flow concentrates at Leeds, King's, Oxford, Addenbrooke's and Glasgow rather than dispersing across general haematology
- Full profiles of ravulizumab (Ultomiris), iptacopan (Fabhalta) and crovalimab (Piasky) spanning IV, oral and subcutaneous mechanisms
- Mechanism, sponsor, trial evidence and NICE status for all three agents, from AstraZeneca/Alexion through Novartis and Roche
- Why ravulizumab (TA698), iptacopan (TA1000) and crovalimab all cleared NICE via the standard Technology Appraisal, not the ultra-rare HST route
- How iptacopan's status as NICE's 1,000th published appraisal resolved earlier uncertainty around its estimated £350,000-400,000 annual WAC
- How fewer than 25 consultants across 15 designated centres manage over 90% of the UK's diagnosed PNH patients
- Why this concentrated prescriber base makes centre-level relationships, not broad specialist outreach, the commercial lever
- What sequence of MHRA approval and NICE standard Technology Appraisal each of the three agents followed to reach NHS commissioning
- Why crovalimab's recommendation for patients aged 12 and over weighing at least 40kg reflects its COMMODORE 2 trial population
- How the ravulizumab-over-eculizumab switch programme has reshaped anti-C5 class share ahead of iptacopan and crovalimab's entry
- Why convenience, not access, is now the deciding factor across IV q8w, oral daily and SC q4w self-injection options
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (MHRA, EMA, NICE), peer-reviewed literature, and live NHS commissioning documentation, not secondary summaries. Findings are independently verified before inclusion.
PNH UK CI sources: MHRA drug approval records, NICE TA698 Ravulizumab for PNH (2021), NICE TA1000 Iptacopan for PNH, APPLY-PNH (NEJM 2023), COMMODORE 1 & 2 trial data, NHS England Highly Specialised Services specification for PNH (2022), and the Leeds National PNH Registry.
- Drug approval dates verified against MHRA and EMA regulatory records
- Clinical trial results verified against published primary sources (NEJM, trial registries)
- NICE Technology Appraisal status verified against published NICE appraisal documents (TA698, TA1000, and crovalimab's recommendation)
- NHS commissioning structure verified against NHS England Highly Specialised Services specification 2022
Frequently asked questions
Commission this brief
AXLRx delivers PNH competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.